JP2023501204A5 - - Google Patents

Info

Publication number
JP2023501204A5
JP2023501204A5 JP2022525171A JP2022525171A JP2023501204A5 JP 2023501204 A5 JP2023501204 A5 JP 2023501204A5 JP 2022525171 A JP2022525171 A JP 2022525171A JP 2022525171 A JP2022525171 A JP 2022525171A JP 2023501204 A5 JP2023501204 A5 JP 2023501204A5
Authority
JP
Japan
Prior art keywords
antigenic peptide
cell
treatment
antigenic
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501204A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/082101 external-priority patent/WO2021094562A2/en
Publication of JP2023501204A publication Critical patent/JP2023501204A/ja
Publication of JP2023501204A5 publication Critical patent/JP2023501204A5/ja
Pending legal-status Critical Current

Links

JP2022525171A 2019-11-15 2020-11-13 Ｂ細胞悪性腫瘍の予防及び治療のための抗原性ペプチド Pending JP2023501204A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19306475 2019-11-15
EP19306475.5 2019-11-15
EP2020079257 2020-10-16
EPPCT/EP2020/079257 2020-10-16
PCT/EP2020/082101 WO2021094562A2 (en) 2019-11-15 2020-11-13 Antigenic peptides for prevention and treatment of b-cell malignancy

Publications (2)

Publication Number Publication Date
JP2023501204A JP2023501204A (ja) 2023-01-18
JP2023501204A5 true JP2023501204A5 (https=) 2023-12-11

Family

ID=75911928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525171A Pending JP2023501204A (ja) 2019-11-15 2020-11-13 Ｂ細胞悪性腫瘍の予防及び治療のための抗原性ペプチド

Country Status (19)

Country Link
US (2) US11759508B2 (https=)
EP (2) EP4357356A3 (https=)
JP (1) JP2023501204A (https=)
CN (1) CN114746112A (https=)
AU (1) AU2020384926B2 (https=)
BR (1) BR112022009100A2 (https=)
CA (2) CA3153470A1 (https=)
DK (1) DK4021487T5 (https=)
ES (1) ES2971929T3 (https=)
FI (1) FI4021487T3 (https=)
HR (1) HRP20240116T1 (https=)
HU (1) HUE065075T2 (https=)
LT (1) LT4021487T (https=)
MX (1) MX2022005704A (https=)
PL (1) PL4021487T3 (https=)
RS (1) RS65262B1 (https=)
SI (1) SI4021487T1 (https=)
SM (1) SMT202400048T1 (https=)
WO (1) WO2021094562A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018065623A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
HRP20230007T1 (hr) 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
JP2025081784A (ja) * 2022-03-01 2025-05-28 ｂｉｔＢｉｏｍｅ株式会社 アミノ酸残基配列を同定するための方法，プログラム及び記録媒体
KR20240017325A (ko) * 2022-07-29 2024-02-07 주식회사 엘지화학 항원 전달용 재조합 융합 단백질 및 이의 이용

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
US7812116B2 (en) * 2003-07-03 2010-10-12 Rush University Medical Center Immunogenic peptides
ES2532896T5 (es) 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
WO2013101690A1 (en) 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
AU2017254477A1 (en) * 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
CN106008695A (zh) * 2016-06-19 2016-10-12 苏州普罗达生物科技有限公司 一种关于cd19免疫原多肽及其用途
WO2018065623A2 (en) * 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
CN111315769A (zh) * 2017-09-06 2020-06-19 加州理工学院 信号传导和抗原呈递双功能受体(sabr)
KR102823291B1 (ko) * 2017-10-09 2025-06-19 엔터롬 에스.에이. 종양-관련된 항원 에피토프의 미생물 서열 변이체
HRP20230007T1 (hr) * 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
WO2020072700A1 (en) * 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines

Similar Documents

Publication Publication Date Title
JP2023501204A5 (https=)
JP5230579B2 (ja) 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
RU2328305C2 (ru) Вакцинная композиция
KR100633212B1 (ko) 백신접종을 위한 융합 단백질 및 조성물의 제조를 위해사용되는 ｍａｇｅ 군으로부터의 종양 관련 항원 유도체및 이들을 암호화하고 있는 핵산 서열
JP2002514658A (ja) β−アミロイド前駆体タンパク質およびユビキチンＢのフレームシフト変異体ならびにその使用
JP2009506762A5 (https=)
Oki et al. Heat shock protein-based cancer vaccines
JP2004154138A (ja) 免疫原性ペプチド
JP2010523471A5 (https=)
JP2012517799A5 (https=)
JP2023529839A5 (https=)
EP0753009A1 (en) Malaria peptides
Hanson et al. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors
WO2019213555A1 (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
EP0862740B1 (en) Oncogene fusion protein peptide vaccines
JP2012513742A5 (https=)
JP2014506114A5 (https=)
CN114746111A (zh) 用于对糖尿病患者进行分层的方法
Reimann et al. DNA vaccines expressing antigens with a stress protein‐capturing domain display enhanced immunogenicity
TW202346363A (zh) 腫瘤抗原、包含所述腫瘤抗原的化合物及其用途
CN104066445A (zh) 用mage-a3免疫治疗剂与braf抑制剂和/或mek抑制剂治疗癌症的方法
JP2013513549A5 (https=)
JP2013521761A5 (https=)
JP2007126442A (ja) 癌特異的抗原
JP2012510794A5 (https=)